What's Happening?
Hospitals across the United States are refusing to participate in a survey conducted by the Department of Health and Human Services (HHS) regarding their prescription drug acquisition costs. This survey, mandated by the Centers for Medicare & Medicaid
Services (CMS), targets hospitals that benefit from the 340B drug discount program, which provides reduced-priced drugs to low-income serving hospitals. The survey's purpose is to verify the amounts hospitals pay for these prescriptions, with the results intended to inform drug payment rates for 2027. However, hospitals are declining to comply, as the HHS lacks the authority to enforce penalties for noncompliance. The deadline for submission was March 31, and the survey is part of ongoing efforts by the agency to regulate drug pricing.
Why It's Important?
The refusal of hospitals to comply with the HHS survey highlights a significant challenge in regulating drug prices within the U.S. healthcare system. The 340B program is crucial for providing affordable medications to underserved communities, and accurate data on drug acquisition costs is essential for setting fair payment rates. The lack of enforcement power by the HHS could undermine efforts to ensure transparency and accountability in drug pricing, potentially affecting the financial sustainability of hospitals that rely on the 340B program. This situation underscores the need for stronger regulatory mechanisms to support healthcare affordability and access.
